Skip to main content

Table 2 Response to imatinib: (n = 87; n = 8 not assessable).

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

 

N pts (%)

Complete Response

4

(4.6)

Partial Response

26

(29.9)

Stable disease

41

(47.1)

Progressive disease

16

(18.4)